DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration

Figure 2

Kaplan-Meier survival curves comparing the high and low expression of DHX37 in different types of cancer in the PrognoScan (a–h) and Kaplan-Meier plotter databases (i–p). (a, b) Survival curves of RFS and OS in two lung cancer cohorts [GSE31210 () and GSE11117 ()]. (c, d) Survival curves of DFS and OS in colorectal cancer cohort (GSE17536, ) and skin cancer cohort (GSE19234, ). (e, f) Survival curves of OS and DSS in two blood cancer cohorts [GSE12417-GPL570 () and GSE2658 ()]. (g, h) Survival curves of DMSF and RFS in the breast cancer cohort (GSE6532-GPL570, ). Kaplan-Meier survival curves comparing the high and low expression of DHX37 in Kaplan-Meier Plotter, OS, and RFS of (i, j) liver hepatocellular carcinoma (LIHC) (k, l) breast cancer (BRCA) (m, n) lung adenocarcinoma (LUAD) (o, p) lung squamous cell carcinoma (LUSC). Red curve represents patients with high expression of DHX37. OS: overall survival; DMSF: distant metastasis-free survival; DFS: disease-free survival; RFS: relapse-free survival; DSS: disease-specific survival.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)

(p)